Table 3 Comparison of clinical features of patients with rheumatoid arthritis with or without serum citrullinated inter-alpha-trypsin inhibitor heavy chain 4
| Â | Total | Citrullinated ITIH4 | p Value | |
|---|---|---|---|---|
+ | – | |||
No. of patients (%) | 60 | 49 (82%) | 11 (18%) | Â |
Age, years | 52.2 ± 1.9 | 51.3 ± 2.2 | 55.9 ± 3.9 | 0.355 |
Females, n (%) | 48 (80%) | 38 (78%) | 10 (91%) | 0.317 |
DAS28-CRP score | 3.9 ± 0.2 | 4.1 ± 0.2 | 3.3 ± 0.4 | 0.040 |
CRP, mg/dl | 2.18 ± 0.30 | 2.46 ± 0.34 | 0.93 ± 0.56 | 0.047 |
Anti-CCP antibodies, U/ml | 131.6 ± 21.6 | 138.9 ± 24.6 | 93.4 ± 39.0 | 0.462 |
 Positive, n (%) | 46 (82%) | 39 (83%) | 7 (78%) | 0.709 |
RF, U/ml | 210.6 ± 46.1 | 242.3 ± 55.0 | 69.5 ± 35.5 | 0.011 |
MMP-3, ng/ml | 198.5 ± 21.8 | 214.7 ± 25.7 | 127.9 ± 20.1 | 0.122 |
PSL use, n (%, mean dose in mg/day) | 51 (85%, 6.9) | 41 (84%, 7.1) | 10 (91%, 6.4) | 0.544 |
MTX use, n (%, mean dose in mg/week) | 40 (67%, 10.1) | 31 (63%, 10.1) | 10 (91%, 10.0) | 0.075 |